Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer

Oncotarget. 2016 Nov 1;7(44):71773-71781. doi: 10.18632/oncotarget.12365.

Abstract

Long intergenic non-protein coding RNA, p53 induced transcript (Linc-pint) is a long noncoding RNA (lncRNA) that regulates tumor cell viability and proliferation. We used qRT-PCR and RNA FISH analysis to evaluate Linc-pint levels in the plasma and tumor tissues of pancreatic cancer (PCa) patients. Our data demonstrate that Linc-pint expression is lower in plasma samples from PCa patients than from healthy individuals, and indicate that plasma Linc-pint levels are more sensitive than CA19-9 for detecting PCa. Our data also show that Linc-pint levels are lower in PCa tumors than in adjacent tissues, carcinoma of the ampulla of Vater (CAV) and cholangiocarcinoma (CCA), and suggest that Linc-pint could be used for distinguishing the cause of malignant obstructive jaundice. Low plasma Linc-pint levels correlate with tumor recurrence, while low tumor Linc-pint levels correlate with poor prognosis for PCa patients after pancreatectomy. These results thus indicate that low plasma Linc-pint expression could serve as a minimally invasive biomarker for early PCa detection, and that low Linc-pint levels in PCa tumors could be used for predicting patient prognosis.

Keywords: CA19-9; Linc-pint; biomarker; pancreatic cancer; prognosis.

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / analysis*
  • CA-19-9 Antigen / blood
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / pathology
  • Prognosis
  • RNA, Long Noncoding / analysis*
  • RNA, Long Noncoding / blood

Substances

  • Biomarkers, Tumor
  • CA-19-9 Antigen
  • RNA, Long Noncoding